분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-06-14 23:27:10 , Hit : 2834
 Vertex licenses Hep C candidates in milestone-heavy deal

Monday, June 13, 2011

By James M. Connolly

Vertex Pharmaceuticals Inc. of Cambridge and Alios BioPharma Inc. of South San Francisco, Calif., have announced a deal under which Vertex will license two Alios compounds designed to be inhibitors of the hepatitis C virus polymerase enzyme.

With the deal, Vertex said it has multiple opportunities to develop new, all-oral combination regimens for chronic hepatitis C. Vertex expects the nucleotide drug candidates, ALS-2200 and ALS-2158, to enter clinical development later this year.

In return for Vertex gaining worldwide rights to the hepatitis C drug candidates, Alios gets a $60 million upfront payment and research and development costs of ALS-2200 and ALS-2158 covered by Vertex. The Cambridge pharmaceutical firm could pay up to $715 million in R&D milestone payments if both drugs are approved, and up to $750 million more if both drug candidates then meet sales milestones.

The announcement came just weeks after Vertex won approval from the U.S. Food and Drug Administration for its hepatitis C drug, Incivek.

“The recent approval of Incivek was a milestone in hepatitis C care, and today’s announcement underscores our long-term commitment to further improving the treatment of this disease with new combinations of medicines,” said Peter Mueller, Ph.D., chief scientific officer and executive vice resident of global research and development at Vertex in a press release. “Alios has discovered anti-HCV nucleotides that have the potential to be leading agents in hepatitis C. Based on impressive in vitro data, we look forward to evaluating ALS-2200 and ALS-2158 together and in combination with our approved and investigational hepatitis C medicines with the goal of creating a highly potent all-oral regimen in the years ahead.”

Approval of Incivek also spurred Vertex to sign a lease for a new headquarters in Boston’s waterfront innovation district.








547   RNAs Regulate Cell Death  이성욱 2011/07/07 2517
546   NIH's Secondhand Shop for Tried-and-Tested Drugs  이성욱 2011/06/27 2354
545   HIV study reveals double jeopardy  이성욱 2011/06/26 2641
544   Protein synthesis: Stop the nonsense  이성욱 2011/06/20 2288
  Vertex licenses Hep C candidates in milestone-heavy deal  이성욱 2011/06/14 2834
542   Hepatitis C mouse model a major milestone  이성욱 2011/06/11 2126
541   Stem cells: The growing pains of pluripotency  이성욱 2011/05/25 2087
540   Vertex hepatitis C drug OK'd, promising more cures  이성욱 2011/05/25 2330
539   WHO to decide fate of smallpox stocks  이성욱 2011/05/24 2454
538   Understanding HIV Latency to Undo It  이성욱 2011/05/23 2454
537   Reprogrammed cells trigger immune reactions in mice  이성욱 2011/05/20 2109
536   The dark matter of disease -NC DNA  이성욱 2011/05/18 2532
535   Sugars recruited in fight against persistent infections  이성욱 2011/05/17 2926
534   Setback for New Stem Cell Treatment  이성욱 2011/05/17 2058
533   Merck’s Hepatitis C Drug Wins F.D.A. Approval  이성욱 2011/05/17 2240
532   Liver repaired with stem cells taken from skin and blood  이성욱 2011/05/14 2363
531   HIV Drug Could Prevent Cervical Cancer, Researchers Discover  이성욱 2011/05/12 2505
530   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3159
529   Stem Cells of 10-Year-Old Help Create Blood Vessel in Life-Saving Surgery  이성욱 2011/05/11 2647
528   Cells Send Signals Via Membrane Nanotubes  이성욱 2011/05/09 2087

[이전 10개] [1]..[31][32][33][34][35][36] 37 [38][39][40]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN